Delving into the Latest Updates on Ombitasvir/Paritaprevir/Ritonavir with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ABT-267/ABT-450/ritonavir, ABT-267/ritonavir/ABT-450, ABT-450/ABT-267/ritonavir

+ [12]

Target

HIV-1 pol x NS3/NS4A x NS5A

Mechanism

HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Chronic hepatitis C genotype 1Hepatitis C, Chronic

Inactive Indication

Compensated cirrhosisFibrosisKidney Failure, Chronic+ [1]

Originator Organization

AbbVie, Inc.

Active Organization

AbbVie Deutschland GmbH & Co. KGAbbVie Biotherapeutics, Inc.

Inactive Organization

AbbVie, Inc.

Drug Highest PhaseApproved

First Approval Date

EU (14 Jan 2015),

Hepatitis C, Chronic

RegulationBreakthrough Therapy (US), Orphan Drug (US), Special Review Project (CN)

Login to view First Approval Timeline

Structure

Molecular FormulaC37H48N6O5S2

InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N

CAS Registry155213-67-5

View All Structures (3)

Clinical trials evaluating DAA have shown excellent rates of SVR and good safety profiles in patients with CHC infection. Real world data from TARGET, TRIO, IFI, DHCR, DALTON-C, as well as those cohorts from Japan, Taiwan and Korea further confirmed clinical trial findings of DAA in routine practice where populations are more complex. However, these populations are different from Chinese for different host and virus characteristics which limit the applicability of results to local practice.
As DAA launched in China since 2017, the availability of INF free DAA treatment will likely lead to better treatment outcome in routine practice, but there are currently no data available to test the hypothesis.
In clinical practice, the uptake of DAA regimen will depend on a combination of physician preference, patient's characteristics and drug access. This study will also identify how these three variables affect DAA regimen uptake.
This study to 1) characterize pts receiving IFN free DAA regimens, 2) represent common practice in China, 3) describe outcome of various INF free DAA therapy, and 4) confirm registration study results.

Start Date06 Mar 2019

Sponsor / Collaborator

Gilead Sciences, Inc.

[+1]

NCT03499639 / CompletedPhase 4IIT

Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study)

Management of patients with hepatitis C virus (HCV) related liver disease with concomitant co-morbidity was challenging, especially in the period before the era of new direct-acting antiviral (DAA) agents. With the introduction of DAAs protocols, the therapeutic options were expanded to endorse many patients that were previously assigned as difficult-to-treat population. Different situations were encountered with co-infection with HCV such as chronic kidney disease (CKD) with its spectrum from mild forms to the end-stage kidney disease (ESKD), patients on hemodialysis (HD), and in post-renal transplant settings. Till now, pooled data about the safety and efficacy of different DAAs regimens in different renal situations are still under evaluation, especially in Egypt, where HCV genotype 4 the most dominating genotype. In Egypt, there were two adopted protocols for patients with HCV and CKD; the sofosbuvir-based combinations and the ombitasvir, paritaprevir, and ritonavir plus ribavirin-based combination. Sofosbuvir was proved to be contraindicated in patients with end-stage renal diseases as its elimination based mainly on renal route that may affect its bioavailability. On the other hand, ombitasvir, paritaprevir, and ritonavir plus ribavirin regimen was proved to be a well-tolerated protocol in non-cirrhotic patients with CKD.

Start Date01 May 2018

Sponsor / Collaborator

Assiut University

[+2]

NCT03549832 / CompletedNot ApplicableIIT

Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin Versus Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin in the Management of Hepatitis C Patients Fauilre to Prior Sofosbuvir/ Daclatasvir (An Open-labeled Randomized Trial)

Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/ paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.

Start Date01 Jan 2018

Sponsor / Collaborator

Assiut University

[+2]

100 Clinical Results associated with Ombitasvir/Paritaprevir/Ritonavir

Login to view more data

100 Translational Medicine associated with Ombitasvir/Paritaprevir/Ritonavir

Login to view more data

100 Patents (Medical) associated with Ombitasvir/Paritaprevir/Ritonavir

Login to view more data

117

Literatures (Medical) associated with Ombitasvir/Paritaprevir/Ritonavir

01 Sep 2023·Therapeutic innovation & regulatory science

Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.

Review

Author: Sabri, Nagwa A ; Solayman, Mohamed H ; El-Marakby, Mai G

BACKGROUND:

Hepatitis C virus (HCV) is the primary contributor to chronic hepatic diseases. A rapid change in the situation took place with the advent of oral direct-acting antivirals (DAAs). However, a comprehensive review of the adverse event (AE) profile of the DAAs is lacking. This cross-sectional study aimed to analyze the reported Adverse Drug Reactions (ADRs) with DAA treatment using data from VigiBase, the WHO Individual Case Safety Report (ICSR) database.

METHODS:

All ICSRs reported to VigiBase with sofosbuvir (SOF), daclatasvir (DCV), sofosbuvir /ledipasvir (SOF/LDV) and ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in Egypt were extracted. Descriptive analysis was performed to summarize patients' and reactions' characteristics. Information components (ICs) and proportional reporting ratios (PRRs) for all reported ADRs were calculated to identify signals of disproportionate reporting. Logistic regression analysis was performed to identify the DAAs association with serious events of concern while adjusting for age, gender, pre-existing cirrhosis, and ribavirin use.

RESULTS:

Out of 2925 reports, 1131 (38.6%) were serious. The most commonly reported reactions; anaemia (21.3%), HCV relapse (14.5%) and headache (14%). For the disproportionality signals; HCV relapse was reported with SOF/DCV (IC 3.65, 95% CrI 3.47-3.79) and SOF/RBV (IC 3.69, 95% CrI 3.37-3.92), while anaemia (IC 2.85, 95% CrI 2.26-3.27) and renal impairment (IC 2.12, 95% CrI 0.7-3.03) were reported with OBV/PTV/r.

CONCLUSION:

The highest severity index and seriousness were reported with SOF/RBV regimen. A significant association was found for OBV/PTV/r with renal impairment and anaemia although being the superior regimen in terms of efficacy. The study findings call for further population-based studies for clinical validation.

01 Oct 2022·Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia

Article

Author: Alotaibi, Anfal ; Alzahrani, Abdullah ; Almutairi, Malak ; Alhomaid, Njood ; Korayem, Ghazwa B ; Hakami, Mashael ; Alghamdi, Abdullah ; Alharthi, Noori ; Alarfaj, Sumaiah J

Background:

The introduction of direct-acting antivirals (DAA) to treat the hepatitis C virus (HCV) overcame many drawbacks of interferon-based therapy. DAA achieved sustained viral response (SVR) rates above 90% and overcame many drawbacks of pegylated interferon regimens.The HCV genotype (GT) distribution varies by geographical area, with GT-4 being most prevalent in the Middle East region, including Saudi Arabia. Yet, the real-world evidence about using DAAs in the Saudi population is limited.Thus, the aim of this study to investigate the effectiveness and safety of DAAs in Saudi patients with HCV infection.

Methods:

A retrospective cohort study included patients treated with DAAs from 2015 to 2017 at a tertiary care hospital in Riyadh, Saudi Arabia. All patients with HCV treated with either ledipasvir plus sofosbuvir (LDS/SOF) ± ribavarin (RBV) or ombitasvir-paritaprevir-ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± RBV were included. Using a per-protocol analysis, the effectiveness outcome was the end-of-treatment response (EOTr) and Sustained virologic reponce12 weeks after competing the regimen (SVR12). The secondary safety outcome was the adverse event related to the therapy reported by the patients.

Results:

A total of 97 patients were included; with the majority infected with GT-4 (64 %), followed by GT-1 (18 %), in addition to 8 % having a mixed GT (1 + 4). The EOTr and SVR12 rates were 98 % and 96 %, respectively. SVR12 was 94.4 % within the LDS/SOF ± RBV group and 97.7 % within the OBV/PTV/r ± DSV ± RBV group. Only 4 % had a response failure due to relapse or breakthrough, and all were infected with mixed GT1 + 4. Medications were well tolerated with minimal side effects, including vomiting, nausea, and weakness.

Conclusion:

DAAs regimens are associated with high rates of SVR12 and are well tolerated with a good safety profile in Saudi HCV-infected patients.

01 Jan 2022·In vivo (Athens, Greece)Q4 · MEDICINE

Glycemic Control in Patients Undergoing Treatment With Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir for Chronic Hepatitis C Infection

Q4 · MEDICINE

Article

Author: Toma, Radu Valeriu ; Toma, Letitia ; Zgura, Anca ; Ifrim, Chen-Peng ; Iliescu, Laura ; Bacinschi, Xenia ; Mercan-Stanciu, Adriana ; Diaconu, Camelia ; Bacalbasa, Nicolae

BACKGROUND/AIM:

Patients with hepatitis C virus (HCV)-associated cirrhosis are more prone to developing type 2 diabetes mellitus than patients with any other etiology of cirrhosis. The main objective of this study was to evaluate the impact of all oral antiviral treatment with ritonavir-boosted paritaprevir/ombitasvir and dasabuvir (OBV/PTV/r + DSV) in patients with chronic genotype 1b HCV infection.

PATIENTS AND METHODS:

We retrospectively evaluated 806 patients who underwent antiviral therapy between December 2015 and July 2019. The laboratory data analyzed were liver function tests, kidney function tests, HCV viremia, fasting glucose levels, and glycosylated hemoglobin.

RESULTS:

Patients with impaired glucose metabolism were predominantly male and of older age compared to patients with normal glucose tolerance, and also had higher levels of transaminases. Proteinuria and higher creatinine levels were found in patients with impaired glucose metabolism. Overall, we found a 98.01% rate of sustained virologic response (SVR), with a non-significant difference between patients with normal and abnormal glucose metabolism. A statistically significant difference in SVR rates in patients with low degrees of fibrosis (F0-F2) versus those with advanced degrees of fibrosis (F3-F4) was found in both groups. Antiviral treatment resulted in significant decreases in fasting glucose levels and glycosylated hemoglobin levels in all patients with impaired glucose metabolism at SVR.

CONCLUSION:

Patients with pre-diabetes, as well as diabetic patients, achieved a better glycemic control after SVR obtained by ritonavir-boosted paritaprevir/ombitasvir and dasabuvir.

2

News (Medical) associated with Ombitasvir/Paritaprevir/Ritonavir

21 Sep 2023

·www.biospace.com

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the appointment of Christopher Holterhoff as Senior Vice President, Head of Business Development. Mr. Holterhoff will lead Bluejay’s business and corporate development function and will play a significant role in Bluejay’s corporate strategy and strategic planning activities. He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics. “I am delighted to welcome Chris to the senior leadership team at Bluejay”, stated Mrs. Chu. “Chris has an outstanding track record in business & corporate development with both public and private biotech and pharma companies. His business development experience, as well as his strategic aptitude will play a critical role as we execute on our vision of building a leading biotechnology company focused on curative treatments for serious viral and liver diseases.” “Bluejay is extremely well-positioned with a pipeline of first-in-class or best-in-class treatment options addressing serious and highly prevalent viral and liver diseases where there exists substantial unmet medical need. I am thrilled to join the organization at such a pivotal time in its development, and I look forward to working with Bluejay’s exceptional team and leveraging my experience in business development to advance the company’s promising pipeline toward approval for patients who are in dire need of new treatment options.” Mr. Holterhoff has nearly two decades of diverse experience encompassing business & corporate development, corporate finance & strategy, and capital markets. Before joining Bluejay, he served as VP, Business & Corporate development at LEXEO Therapeutics, where he led all business development, strategic transactions and played a significant role in the company’s capital raising activities. Prior to LEXEO, Mr. Holterhoff served as executive director of business development at Amicus Therapeutics where he executed on new strategic business opportunities for Amicus’ gene therapy pipeline, including license agreements, M&A transactions, and R&D collaborations, and led the alliance management function. Earlier in his career, he worked in healthcare investment banking at MTS Health Partners, where he advised public and private biotechnology and pharmaceutical companies on strategic buy and sell side transactions and financings and served as a senior publishing equity research analyst at Oppenheimer & Co. Inc., providing coverage of biotechnology and pharmaceutical companies. Mr. Holterhoff holds an MBA from Columbia University, MS in Biotechnology from Georgetown University, and BS from Providence College. Mr. Holterhoff joins a seasoned executive leadership team, including: Keting Chu, M.D., Ph.D., founder and chief executive officer, was previously a partner at LYFE Capital and venture partner at Apple Tree Partners, and was responsible for venture philanthropy at The Leukemia and Lymphoma Society. Dr. Chu was also the CEO of several companies, including Mission Therapeutics, DigitAB, and BioCubed Corporation. Earlier in her career, she held R&D leadership roles at Five Prime Therapeutics and Chiron Corporation. Hassan Javanbakht, Ph.D., chief scientific officer, was previously at Hoffman La-Roche, Gilead sciences and SQZ biotechnologies where he worked on developing novel antivirals and immunomodulators to treat HIV, HBV, influenza and other infectious diseases. He was part of the team that advanced Elipida® (RO4970335), a potent and highly selective NNRTI, into clinical development . He led the teams that developed a first-in-class small-molecule viral expression inhibitor (RG7834) and a liver-targeted anti-HBV locked nucleic acid (RG6004). His work also led to discovery of PAPD5/7 as host factors for HBV expression. He has authored more than 45 peer-reviewed scientific publications in high-impact journals and holds more than 11 issued patents and applications. Nancy Shulman, M.D., CMO, has over 20 years of clinical development experience including at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was the vice president of translational medicine. She brings broad clinical development experience ranging from first-in-human and translational studies through Phase 4 studies, including extensive experience in the virology/hepatology disease area, but also in immunology and oncology. She has been a part of multiple INDs and was a key leader on the NDA approvals of the HCV antivirals Viekira Pak®, Viekirax®, and Mavyret®. Kevin Lin, M.D., vice president of development, has over 30 years of experience in the biotechnology industry in the areas of process development, technology transfer, scale up, troubleshooting, GMP manufacturing, and CMC regulatory submission. He has worked at several biotech companies, such as Bayer Healthcare, Catalant, Avid Bioservices, ImmunityBio, and Kindred Biosciences. Jeff Zablocki, Ph.D., vice president of chemistry, has led chemistry teams at AbbVie, Gilead, CV Therapeutics, Amgen, and Searle. Dr. Zablocki has discovered 15 development compounds including 3 approved agents: Lexiscan™ – an adenosine A2A agonist used in over 60 million patients as a pharmacological stress agent capturing a large market share; Ranexa™ for stable angina; and Voxilaprevir™ for Hepatitis C where he helped address pre-clinical metabolism challenges by applying novel medicinal chemistry approaches. About Bluejay Therapeutics Bluejay Therapeutics is a clinical stage private biopharmaceutical company committed to developing effective treatments and cures for viral and liver diseases ( ). Its initial target indications are CHB and CHD, diseases that have a global prevalence and an urgent need for improved medical solutions. Bluejay is advancing two potential therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and orally liver-targeted HBV transcript inhibitors. The company has developed a platform for liver-directed drug targeting, with potential applications to multiple therapeutic agents. For more information on potential collaborations with Bluejay Therapeutics regarding partnering opportunities or preclinical or clinical research programs, please contact us at info@bluejaytx.com.

Executive Change

08 Feb 2023

·www.biospace.com

Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.

SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointed Regis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, MicuRx Pharmaceuticals, Inc. He oversees new drug development programs and clinical activities in the United States, Europe and other regions. Dr. Vilchez earned an M.D. from the Universidad Autónoma de Centro América in Costa Rica and a Ph.D. from Baylor College of Medicine in Houston, Texas, the United States. He completed an internal medicine residency at Robert Wood Johnson Medical School, a clinical infectious diseases fellowship at the University of Pittsburgh, and a molecular virology fellowship at Baylor College of Medicine. Prior to entering the biopharmaceutical industry, Dr. Vilchez was full time faculty in the Departments of Medicine and Molecular Virology & Microbiology at Baylor College of Medicine. Dr. Vilchez has served in multiple R&D roles at Boehringer Ingelheim, Merck, Roche, Abbott/AbbVie, Mallinckrodt Pharmaceuticals and other smaller biotechnology companies. In those roles, Dr. Vilchez has been a key contributor to the global development of new therapies such as Vicriviroc, Victrelis, Viekirax, Technivie, Ocaliva, Terlivaz, and StrataGraft. Dr. Vilchez has co-authored more than 100 peer-reviewed scientific publications in high impact biomedical journals such as the New England Journal of Medicine, The Lancet, and Clinical Microbiology Reviews. The leadership of Dr. Vilchez will enhance MicuRx's global R&D programs and clinical activities. MicuRx is rapidly expanding its business and assembling an international expert team with extensive experience and an innovative spirit to develop a robust global R&D organization. Moving forward, MicuRx will remain focused on advancing its anti-infective product pipeline, and provide more effective and safer treatment options for patients around the world. View original content to download multimedia: SOURCE MicuRx Pharmaceuticals Company Codes: Shanghai:688373, Shanghai:688373.SS

Executive Change

100 Deals associated with Ombitasvir/Paritaprevir/Ritonavir

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ombitasvir/Paritaprevir/Ritonavir	J05AP53	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Chronic hepatitis C genotype 1	CN	AbbVie Biotherapeutics, Inc.	20 Sep 2017
Hepatitis C	US	AbbVie, Inc.	24 Jul 2015
Hepatitis C, Chronic	EU	AbbVie Deutschland GmbH & Co. KG	14 Jan 2015
Hepatitis C, Chronic	IS	AbbVie Deutschland GmbH & Co. KG	14 Jan 2015
Hepatitis C, Chronic	LI	AbbVie Deutschland GmbH & Co. KG	14 Jan 2015
Hepatitis C, Chronic	NO	AbbVie Deutschland GmbH & Co. KG	14 Jan 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cirrhosis	Phase 3	KR	AbbVie, Inc.	16 Jul 2015
Kidney Failure, Chronic	Phase 3	-	AbbVie, Inc.	23 Sep 2014
Compensated cirrhosis	Phase 3	-	AbbVie, Inc.	01 Oct 2012
Fibrosis	Phase 3	-	AbbVie, Inc.	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02461745 (CTgov)	Phase 4	Chronic hepatitis C genotype 1	200	OMBITASVIR/PARITAPREVIR/RITONAVIR+dasabuvir+ribavirin (Genotype 1a)	jxxqouovmt(ssikoiktzx) = izhrbtdeoe yeeudzdqgg (rnhgtedzje, ngllpzzdhm - dxcuknxckw) View more	-	22 Jan 2021
				OMBITASVIR/PARITAPREVIR/RITONAVIR+dasabuvir (Genotype 1b)	jxxqouovmt(ssikoiktzx) = xrptaylssv yeeudzdqgg (rnhgtedzje, lryoaymxuv - suqrvkqmwm) View more
NCT02992457 (Pubmed \| Arch Virol)	Phase 4	Hepatitis C	104	Sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin	jxthrtivbl(djvlrzwkvj) = lmrxowjqls dzlujwjfsa (gtriwspfmx )	-	01 Jul 2020
				Sofosbuvir/simeprevir/daclatasvir Sofosbuvir/simeprevir/daclatasvir Sofosbuvir/simeprevir/daclatasvir + ribavirin	jxthrtivbl(djvlrzwkvj) = fdpajdtnzy dzlujwjfsa (gtriwspfmx )
NCT02874066 (CTgov)	Phase 4	Hepatitis C	46	PTV/r/OBV/DSV	lnguoaqtjp(qbnorsdcih) = twneimewld iwxrxezkpc (lkitdrtuli, xcxhqaqlor - hwqqtglfdf) View more	-	19 Jul 2019
SP138 (ERA2019)	Not Applicable	-	53	Ombitasvir 50 mg / Paritaprevir 150 mg / Ritonavir 100 mg	bgdyqttnqv(utwdbbugjt) = Anemia was observed during in 7 patients (13.2%), which required transfusion, erythropoietin therapy, and modification of RBV dose to be every other day ocybufgzoq (mzisnodflt )	Positive	13 Jun 2019
NCT02194998 (C_ASCENT, CTgov)	Phase 2	Chronic hepatitis C genotype 1 \| Coinfection	46	Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)+Dasabuvir (DSV)+ribavirin (RBV) (Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks])	hkwfymmmpm(sycjdoqobp) = vhmnuqfpjz sebugrftag (lixsrfgxcu, poapneaafj - jfcepezkcm) View more	-	04 Jun 2019
				Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)+Dasabuvir (DSV)+ribavirin (RBV) (Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks])	hkwfymmmpm(sycjdoqobp) = bpfblskmsk sebugrftag (lixsrfgxcu, kgxrilntox - dipgxllhci) View more
TOPAZ-I and TOPAZ-II (EASL2019)	Phase 3	Hepatitis C	2,211	ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin	ykyzvpxobt(jwuhewxzqy) = eydaxaohij hxzvojaxkv (zohfxhwkvi )	-	13 Apr 2019
EASL2019	Not Applicable	Fibrosis, Liver \| Hepatitis C	3,067	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 8 weeks	jfvsavtzha(vksitxpvai) = rnhefpppit iwpzizinbb (lopybluhgf )	Positive	11 Apr 2019
				Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 12 weeks	jfvsavtzha(vksitxpvai) = gktuyyhhqy iwpzizinbb (lopybluhgf )
NCT03122132 (Pubmed \| Liver Int)	Not Applicable	Hepatitis C	211	Paritaprevir/ritonavir, ombitasvir + dasabuvir (PTV/r/OBV/DSV)	nkccknwgtf(oqyweykykl) = cojwahabxw jphksosrww (pgukctkxvo ) View more	-	01 Jan 2019
NCT01672983 (M12-536, GIFT II, Pubmed)	Phase 2/3	Hepatitis C	110	ombitasvir (HCV genotype 2a-infected patients)	hskezkertj(sovkjviggj) = virfybmdbu kvfneyxfds (okramlxihm ) View more	-	01 Jan 2018
				ombitasvir (HCV genotype 2b-infected patients)	hskezkertj(sovkjviggj) = agjroqglzx kvfneyxfds (okramlxihm ) View more
NCT02487199 (CTgov)	Phase 3	Kidney Failure, Chronic \| Hepatitis C \| Hepatitis C, Chronic	18	ombitasvir/paritaprevir/ritonavir+dasabuvir (HCV GT1a (3-DAA))	cdcdstbfqj(hwklaqntrd) = hvmhrxeopj pzpznhizrs (wociyouazn, dpsntfogwc - llfrrbfcmm) View more	-	04 Dec 2017
				ombitasvir/paritaprevir/ritonavir (HCV GT4 (2-DAA))	cdcdstbfqj(hwklaqntrd) = msilbndedm pzpznhizrs (wociyouazn, lolvhoqsic - sgqjqaqwmj) View more